Core Points - The company held its first extraordinary general meeting of shareholders on September 5, 2025, with no rejected proposals [1] - The meeting was attended by 57 ordinary shareholders, representing 127,097,347 voting rights, which accounts for 32.2097% of the total voting rights of the company [1] - All non-cumulative voting proposals were approved with a significant majority, with the highest approval rate being 99.6214% for one of the proposals [2][3] Meeting Details - The meeting was convened by the board of directors and chaired by Mr. Li Lin, utilizing a combination of on-site and online voting methods [1] - The voting procedures complied with the Company Law and the company's articles of association [1] - Legal representatives confirmed that the meeting's convening and voting procedures were in accordance with relevant laws and regulations [4] Voting Results - The voting results showed overwhelming support for the proposals, with the highest number of votes in favor reaching 126,616,255, representing 99.6214% [2][3] - The dissenting votes were minimal, with the highest opposition being 416,960, which is only 0.3280% of the total votes [2] - The proposals included the election of several directors, all of which were passed with significant majorities [3][4]

证券代码：688468 证券简称：科美诊断 公告编号：2025-019 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券 交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引 第1号——规范运作》等法律、法规、规范性文件及《科美诊断技术股份有限公 司章程》等有关规定，2025年9月5日，科美诊断技术股份有限公司（以下简称 "公司"）召开2025年第一次临时股东会，选举产生了第三届董事会成员。同 日，公司召开第三届董事会第一次会议，选举产生了董事长、专门委员会委员， 并聘任高级管理人员以及证券事务代表。现将相关情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025年9月5日公司召开2025年第一次临时股东会，选举李临先生、黄正铭 先生、黄燕玲女士、周琪女士、张俊杰先生、Zhiyun Wang女士担任公司第三届 董事会非独立董事；选举宣建伟先生、孟召伟先生、刘宁悦女士担任公司第三 届董事会独立董事。本次股东会选举的6名非独立董事和3名 ...

2025年第一次临时股东会决议公告 证券代码：688468 证券简称：科美诊断 公告编号：2025-018 科美诊断技术股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 9 月 5 日 （二） 股东会召开的地点：北京市海淀区永丰基地丰贤中路 7 号北科现代制造 园孵化楼 B 座二层科美诊断技术股份有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 57 | | --- | --- | | 普通股股东人数 | 57 | | 2、出席会议的股东所持有的表决权数量 | 127,097,347 | | 普通股股东所持有表决权数量 | 127,097,347 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 32.2097 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

上海市通力律师事务所 关于科美诊断技术股份有限公司 2025 年第一次临时股东会的法律意见书 致:科美诊断技术股份有限公司 上海市通力律师事务所(以下简称"本所")接受科美诊断技术股份有限公司(以下简称 "公司")的委托,指派本所黄雅程律师、许宸律师(以下简称"本所律师")根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和规范性文 件(以下统称"法律法规")及《科美诊断技术股份有限公司章程》(以下简称"公司章程") 的规定就公司 2025 年第一次临时股东会(以下简称"本次股东会")相关事宜出具法律意 见。 本所律师已经对公司提供的与本次股东会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中的所有签 署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有效 的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东会召集和召开的程序、出席本次股东会人员资格 和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见,并不对 本次股东会所审议的 ...

据证券之星公开数据整理，近期科美诊断（688468）发布2025年中报。根据财报显示，科美诊断净利润 同比下降68.24%。截至本报告期末，公司营业总收入1.65亿元，同比下降27.03%，归母净利润2434.08 万元，同比下降68.24%。按单季度数据看，第二季度营业总收入8331.53万元，同比下降27.04%，第二 季度归母净利润979.8万元，同比下降74.38%。 证券之星价投圈财报分析工具显示： 业务评价：公司去年的ROIC为7.54%，资本回报率一般。去年的净利率为29.13%，算上全部成本后， 公司产品或服务的附加值高。从历史年报数据统计来看，公司上市以来中位数ROIC为10.14%，投资回 报也较好，其中最惨年份2017年的ROIC为-135.16%，投资回报极差。公司历史上的财报相对一般 （注：公司上市时间不满10年，上市时间越长财务均分参考意义越大。），公司上市来已有年报3份， 亏损年份2次，显示生意模式比较脆弱。 偿债能力：公司现金资产非常健康。 商业模式：公司业绩主要依靠营销驱动。需要仔细研究这类驱动力背后的实际情况。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31 ...

Core Insights - The company reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved a revenue of 165 million yuan, representing a year-on-year decrease of 27.03% [1] - The net profit attributable to shareholders was 24.34 million yuan, down 68.24% compared to the previous year [1] - The non-recurring net profit was 15.92 million yuan, reflecting a decline of 77.35% year-on-year [1] - Basic earnings per share stood at 0.06 yuan [1]

Group 1 - Hailiang Co., Ltd. achieved a revenue of 44.476 billion yuan, a year-on-year increase of 1.17%, and a net profit of 711 million yuan, a year-on-year increase of 15.03% [1] - Yinfai Storage reported a revenue of 543 million yuan, a year-on-year decrease of 18.97%, and a net profit of 62.347 million yuan, a year-on-year decrease of 20.05% [1] - Huamao Technology achieved a revenue of 1.108 billion yuan, a year-on-year increase of 14.42%, and a net profit of 137 million yuan, a year-on-year increase of 3.21% [2] Group 2 - Postal Savings Bank reported a revenue of 179.446 billion yuan, a year-on-year increase of 1.5%, and a net profit of 49.228 billion yuan, a year-on-year increase of 0.85% [4] - Bright Dairy achieved a revenue of 12.472 billion yuan, a year-on-year decrease of 1.9%, and a net profit of 217 million yuan, a year-on-year decrease of 22.53% [6] - Pianzaihuang reported a revenue of 5.379 billion yuan, a year-on-year decrease of 4.81%, and a net profit of 1.442 billion yuan, a year-on-year decrease of 16.22% [7] Group 3 - Great Wall Motors achieved a revenue of 92.335 billion yuan, a year-on-year increase of 0.99%, and a net profit of 6.337 billion yuan, a year-on-year decrease of 10.21% [9] - Haowei Group reported a revenue of 13.956 billion yuan, a year-on-year increase of 15.42%, and a net profit of 2.028 billion yuan, a year-on-year increase of 48.34% [10] - Batian Co., Ltd. achieved a revenue of 2.543 billion yuan, a year-on-year increase of 63.93%, and a net profit of 456 million yuan, a year-on-year increase of 203.71% [12] Group 4 - Yuxin Technology reported a revenue of 1.415 billion yuan, a year-on-year decrease of 5.01%, and a net profit of 220 million yuan, a year-on-year increase of 35.26% [14] - Zhongti Industry reported a revenue of 787 million yuan, a year-on-year decrease of 25.24%, and a net loss of 24.3955 million yuan [15] - Kemei Diagnostics achieved a revenue of 165 million yuan, a year-on-year decrease of 27.03%, and a net profit of 24.3408 million yuan, a year-on-year decrease of 68.24% [16] Group 5 - Huatai Co., Ltd. reported a revenue of 6.409 billion yuan, a year-on-year decrease of 1.86%, and a net profit of 67.6382 million yuan, a year-on-year decrease of 63.13% [17] - Fudan Fuhua reported a revenue of 326 million yuan, a year-on-year increase of 2.20%, and a net loss of 711.58 million yuan [19] - Haili Co., Ltd. achieved a revenue of 12.426 billion yuan, a year-on-year increase of 13.16%, and a net profit of 333.546 million yuan, a year-on-year increase of 693.76% [21] Group 6 - Xintong New Science reported a revenue of 61.852 million yuan, a year-on-year increase of 8.49%, and a net loss of 30.393 million yuan [22] - Newzhisoft achieved a revenue of 897 million yuan, a year-on-year decrease of 3.40%, and a net profit of 30.3531 million yuan, a year-on-year increase of 42.84% [24] - Maolai Optics reported a revenue of 319 million yuan, a year-on-year increase of 32.26%, and a net profit of 32.7555 million yuan, a year-on-year increase of 110.36% [25] Group 7 - Qianjin Pharmaceutical achieved a revenue of 1.818 billion yuan, a year-on-year decrease of 5.52%, and a net profit of 128 million yuan, a year-on-year increase of 8.50% [28] - Quanfeng Automotive reported a revenue of 1.218 billion yuan, a year-on-year increase of 18.90%, and a net loss of 167 million yuan [29] - Zhongjin Lingnan's application for a specific issuance of A-shares has been accepted by the Shenzhen Stock Exchange [31] Group 8 - Zhonglv Electric achieved a revenue of 2.333 billion yuan, a year-on-year increase of 29.30%, and a net profit of 618 million yuan, a year-on-year increase of 33.06% [33] - Sanhuan Group reported a revenue of 4.149 billion yuan, a year-on-year increase of 21.05%, and a net profit of 1.237 billion yuan, a year-on-year increase of 20.63% [35] - China Energy Construction achieved a revenue of 212.091 billion yuan, a year-on-year increase of 9.18%, and a net profit of 28.02 billion yuan, a year-on-year increase of 0.72% [37] Group 9 - Liou Co., Ltd. reported a revenue of 9.635 billion yuan, a year-on-year decrease of 9.62%, and a net profit of 478 million yuan, turning from a loss to profit [38] - Suzhou Bank achieved a revenue of 6.504 billion yuan, a year-on-year increase of 1.81%, and a net profit of 3.134 billion yuan, a year-on-year increase of 6.15% [40] - Shunxin Agriculture reported a revenue of 4.593 billion yuan, a year-on-year decrease of 19.24%, and a net profit of 173 million yuan, a year-on-year decrease of 59.09% [43] Group 10 - Tongfu Microelectronics achieved a revenue of 13.038 billion yuan, a year-on-year increase of 17.67%, and a net profit of 412 million yuan, a year-on-year increase of 27.72% [44] - Weidao Nano reported a revenue of 1.05 billion yuan, a year-on-year increase of 33.42%, and a net profit of 192 million yuan, a year-on-year increase of 348.95% [44] - ZTE Corporation achieved a revenue of 715.53 billion yuan, a year-on-year increase of 14.51%, and a net profit of 50.58 billion yuan, a year-on-year decrease of 11.77% [46]

Core Insights - The company reported a revenue of 165 million yuan for the first half of 2025, representing a year-on-year decline of 27.03% [1] - The net profit for the same period was 24.34 million yuan, showing a significant decrease of 68.24% compared to the previous year [1] Financial Performance - Revenue: 165 million yuan, down 27.03% year-on-year [1] - Net Profit: 24.34 million yuan, down 68.24% year-on-year [1]

Financial Performance - The company reported a significant increase in revenue for the first half of 2025, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[12]. - The company reported a revenue of CNY 164.62 million for the first half of the year, a decrease of 27.03% compared to the same period last year[20]. - The total profit for the period was CNY 27.83 million, down 67.14% year-on-year, while the net profit attributable to shareholders decreased by 68.24% to CNY 24.34 million[20]. - Basic and diluted earnings per share were both CNY 0.06, reflecting a decline of 68.42% compared to the previous year[19]. - The net cash flow from operating activities decreased by 48.70% to CNY 39.78 million, primarily due to reduced sales collections[20]. - The company achieved operating revenue of 164.62 million yuan, a decrease of 27.03% compared to the same period last year[47]. - Net profit attributable to the parent company was 24.34 million yuan, down 68.24% year-on-year[47]. - The company reported a net loss distribution to owners of 49,324,143.30, reflecting challenges in profitability[155]. Market Outlook and Strategy - The company provided a positive outlook for the second half of 2025, projecting a revenue growth of 20% to 30% based on current market trends and product demand[12]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish partnerships with local distributors by Q4 2025[12]. - The company is actively responding to industry challenges by optimizing product structure and enhancing operational efficiency[20]. - The company is focusing on integrating AI and big data to enhance product usability and accuracy in immunodiagnostics[44]. - The company is expanding its market presence by transitioning from single products to comprehensive laboratory solutions, improving efficiency for medical institutions[44]. Research and Development - Research and development efforts are focused on innovative diagnostic technologies, with an investment of RMB 50 million allocated for the development of next-generation testing kits[12]. - The company's R&D expenditure accounted for 21.68% of its operating revenue, an increase of 4.12 percentage points from the previous year[19]. - The company has developed 87 products in the LiCA® series, covering common clinical testing items in infectious diseases, tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers, and inflammation[40]. - The company is actively developing clinical diagnostic tools for Alzheimer's disease and cancer, aiming for early detection and personalized treatment[48]. - The company has ongoing projects with a total expected investment of ¥50,000,000 for the LiCA® homogeneous immunoassay reagent development, with ¥1,499,040 invested in the current period[73]. Product Development and Innovation - New product launches included the LiCA® series, which has shown a 30% improvement in sensitivity compared to previous models, enhancing the company's competitive edge in the market[12]. - The company has established a proprietary chemiluminescence technology platform and developed the LiCA® series of diagnostic products[26]. - The LiCA® series products demonstrate superior performance with sensitivity rates of 96.39% and specificity rates of 99.95%, outperforming international leading brands[52]. - The LiCA® 800 instrument can achieve a maximum testing speed of 600 tests per hour, significantly surpassing international leading brands[40]. - The company has obtained 221 domestic medical device registration certificates and 338 authorized patents, including 142 invention patents, as of June 30, 2025[37]. Compliance and Governance - The company has no significant non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[6]. - There are no violations of decision-making procedures regarding external guarantees, maintaining compliance with regulatory standards[6]. - The board of directors confirmed that all members attended the meeting, ensuring transparency and governance in decision-making processes[4]. - The report emphasizes the importance of risk management, detailing potential risks in the operational environment and strategies to mitigate them[3]. Shareholder and Equity Management - The company has not proposed any profit distribution or capital reserve transfer plans for the half-year period[92]. - The company has implemented a stock incentive plan, which was approved in December 2021, to motivate and retain key personnel[93]. - The company has approved the cancellation of 963,000 shares of unvested restricted stock due to performance criteria not being met for the second vesting period[95]. - The company has committed to ensuring that the public offering of shares does not involve any fraudulent issuance, with a buyback program initiated within five working days if conditions are not met[98]. - The company has a long-term commitment to fulfill its promises regarding profit distribution and shareholder returns post-listing[99]. Financial Position and Assets - The total assets at the end of the reporting period were CNY 1.77 billion, a decrease of 3.32% from the previous year[20]. - The net assets attributable to shareholders decreased by 1.76% to CNY 1.39 billion[20]. - The company's total current assets decreased to RMB 1,016,759,119.84 from RMB 1,067,681,904.23 in the previous period[134]. - The company's fixed assets as of June 30, 2025, were valued at RMB 441,702,666.38, a decrease from RMB 453,868,944.92 at the end of 2024[134]. - Total liabilities decreased by 8.60% to CNY 380.09 million, resulting in a debt-to-asset ratio of 21.46%[77].

证券代码：688468 证券简称：科美诊断 公告编号：2025-017 科美诊断技术股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 | 项目 | 金额 | | --- | --- | | 募集资金总额 | 293,150,000.00 | | 减：发行有关费用 | 44,593,051.99 | | 募集资金净额 | 248,556,948.01 | | 减：募集资金累计使用金额（包括置换先期投入金额） | 256,420,885.27 | | 其中：新建体外诊断试剂生产基地项目 | | | 123,143,353.57 | | --- | --- | --- | --- | | LiCA®试剂与配套仪器研发（实验室）项目 | | | 89,094,974.74 | | LiCA®试剂与关键生物原料研发项目 | | | 44,182,556.96 | | 减：支付发行费用的税金金额 | | | 2,128,301.88 | | 减：期末 ...